Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Receivables - Other: 2019-2022

  • 4D Molecular Therapeutics' Receivables - Other changed negligibly% to $700,000 in Q4 2022 from the same period last year, while for Dec 2022 it was $700,000, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $700,000 for FY2022, which is negligibly% changed negligibly from last year.
  • According to the latest figures from Q4 2022, 4D Molecular Therapeutics' Receivables - Other is $700,000, which was down 0.00% from $700,000 recorded in Q4 2021.
  • In the past 5 years, 4D Molecular Therapeutics' Receivables - Other ranged from a high of $700,000 in Q4 2021 and a low of $149,000 during Q4 2019.
  • Its 2-year average for Receivables - Other is $653,667, with a median of $700,000 in 2022.